Ignite Creation Date:
2025-12-24 @ 9:56 PM
Ignite Modification Date:
2026-01-03 @ 5:09 PM
Study NCT ID:
NCT06858332
Status:
RECRUITING
Last Update Posted:
2025-08-03
First Post:
2025-02-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Sponsor:
Novartis Pharmaceuticals
Organization:
Study Overview
Official Title:
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Status:
RECRUITING
Status Verified Date:
2025-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STaRT
Brief Summary:
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.
Detailed Description:
This study will consist of several phases (consecutive stages):
Phase I: a cross-sectional study of Lp(a) level with ASCVD patients
Phase II:
* A non-interventional, prospective, cohort study with the phase I patients
* A cross-sectional study of Lp(a) levels with relatives of phase I patients
* A non-interventional, prospective, cohort study with patients' relatives
Phase I: a cross-sectional study of Lp(a) level with ASCVD patients
Phase II:
* A non-interventional, prospective, cohort study with the phase I patients
* A cross-sectional study of Lp(a) levels with relatives of phase I patients
* A non-interventional, prospective, cohort study with patients' relatives
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: